Advanced search
Publication Cover
Current Medical Research and Opinion Volume 39, 2023 - Issue 7
Submit an article Journal homepage
2,120
Views
0
CrossRef citations to date
0
Altmetric
Cardiovascular Medicine

Lipoprotein(a) and the risk of recurrent coronary heart disease: the Dubbo Study

Leon A. Simonsa School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8082-6416
ORCID Icon &
Judith Simonsb School of Clinical Medicine, St Vincent’s Hospital, Sydney, Australia
Pages 933-938 | Received 18 Mar 2023, Accepted 12 May 2023, Published online: 12 Jun 2023

References

  • Emerging Risk factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality. JAMA. 2009;302:412–423.
  • Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853.
  • Nordestgaard BG, Langsted A. Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics and biology. J Lipid Res. 2016;57(11):1953–1975.
  • Handhle A, Viljoen A, Wierzbicki AS. Elevated Lipoprotein(a): background, current insights and future potential therapies. Vasc Health Risk Manag. 2021;17:527–542.
  • Parthymos I, Kostapanos MS, Mikhailidis DP, et al. Lipoprotein(a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview. Eur J Prev Cardiol. 2022;29(5):739–755.
  • Wilson SDP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the national Lipid Association. J Clin Lipidol. 2019;13(3):374–392.
  • Langsted A, Nordestgaard BG. Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality? Curr Opin Lipidol. 2020;31(3):125–131.
  • O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition and cardiovascular risk. Circulation. 2019;139(12):1483–1492.
  • Bittner VA, Szarek M, Aylward PE, et al. Effect of alirocumab on Lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75(2):133–144.
  • Simons LA, Simons J, Friedlander Y, et al. LDL-cholesterol predicts a first CHD event in senior citizens, especially so in those with elevated Lipoprotein(a): Dubbo study of the elderly. Heart Lung Circ. 2018;27(3):386–389.
  • Madsen CM, Kamstrup PR, Langsted A, et al. Lipoprotein(a)-lowering by 50mg/dL (105nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention. A population-based study. Arterioscler Thromb Vasc Biol. 2020;40(1):255–266.
  • Liu HH, Cao Y-X, Jin J-L, et al. Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease. Heart. 2020;106(16):1228–1235.
  • Takahashi D, Wada H, Ogita M, et al. Impact of Lipoprotein(a) as a residual risk factor in long-term cardiovascular outcomes in patients with acute coronary syndrome treated with statins. Am J Cardiol. 2022;168:11–16.
  • Colantonio LD, Bittner V, Safford MM, et al. Lipoprotein(a) and the risk for coronary heart disease and ischemic stroke events among black and white adults with cardiovascular disease. J Am Heart Assoc. 2022;11(11):e025397.
  • Kaiser Y, Daghem M, Tzolos E, et al. Association of Lipoprotein(a) with atherosclerotic plaque progression. J Am Coll Cardiol. 2022;79(3):223–233.
  • Simons LA, McCallum J, Simons J, et al. The Dubbo study: an Australian prospective community study of the health of elderly. Aust N Z J Med. 1990;20(6):783–789.
  • Simons LA, McCallum J, Friedlander Y, et al. Dubbo study of the elderly: sociological and cardiovascular risk factors at entry. Aust N Z J Med. 1991;21(5):701–709.
  • Enkhmaa B, Anuurad E, Zhang W, et al. Significant associations between Lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans. Atherosclerosis. 2014;235(1):223–229.
  • Marcovina SM, Albers JJ. Lipoprotein(a) measurements for clinical application. J Lipid Res. 2016;57(4):526–537.
  • Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244–255. 16
  • Swerdlow DI, Rider DA, Yavari A, et al. Treatment and prevention of Lipoprotein (a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. Cardiovasc Res. 2022;118(5):1218–1231.
  • ClinicalTrials.gov. Assessing the impact of Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD (Lp(a)Horizon). NCT04023552, 10-10; 2022.
  • ClinicalTrials.gov. Olpasiran trials of cardiovascular events and Lipoprotein(a) reduction (OCEAN(a))- outcomes trial. NCT05581303, 2-2; 2023.
  • Dagen MM, Packard CJ, Shepherd J. A comparison of commercial kits for the measurement of lipoprotein(a). Ann Clin Biochem. 1991;28(4):359–364.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.